Department of Microbiology, Nicolaus Copernicus University, The Ludwik Rydygiers Collegium Medicum, Bydgoszcz, Poland.
J Antibiot (Tokyo). 2024 Aug;77(8):548-551. doi: 10.1038/s41429-024-00734-2. Epub 2024 May 8.
Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTS cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml for ESβL-positive strains and from 0.25 to 256 µg ml for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.
泊沙康唑是一种具有广谱活性的新型氨基糖苷类药物，可对抗多种耐药菌株。本研究旨在评估肺炎克雷伯菌对泊沙康唑和其他氨基糖苷类药物的敏感性。评估了泊沙康唑与头孢他啶-阿维巴坦或美罗培南联合使用对选定菌株的活性。该研究涉及 60 株 ESβL 阳性肺炎克雷伯菌和 50 株碳青霉烯酶阳性菌株。使用梯度条带法测试氨基糖苷类药物的敏感性。使用 MTS 交叉协同法评估泊沙康唑和头孢他啶-阿维巴坦或美罗培南的体外活性。泊沙康唑对 ESβL 阳性菌株的 MIC 范围为 0.19 至 4 μg/ml，对碳青霉烯酶阳性菌株的 MIC 范围为 0.25 至 256 μg/ml，对肺炎克雷伯菌表现出高度活性。没有发现任何组合的拮抗作用。泊沙康唑对分析菌株表现出优异的体外活性，表明该抗生素可能是治疗多药耐药肺炎克雷伯菌引起的感染的有效治疗选择。
